With the pressure on, the company decided to redefine its business strategy by focusing on neurology, immunology, and hemophilia. The company planned to launch five new drugs, in the next 3 years and hire a new head of research to propel their pipeline further. Biogen Idec pipelines began to pay off with Fampyra a drug that helps walking ability in patients with MS was FDA approved in 2010. Shortly after, the company was able to expand upon their blockbuster drug Rituxan, a monoclonal antibody for treating cancer. In 2011, the FDA approved for use in patients with Chronic lymphocytic leukemia. Things got even better for Biogen Idec as a study for their blockbuster pipeline drug Tecfidera, for treatment of MS, showed no safety concerns in clinical trials. In 2011, Biogen Idec's revenue surpassed $5 billion, with sales increasing and the company's thriving pipeline, investors began flocking to the stock.